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Aspartate/asparagine-β-hydroxylase crystal
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factor-like domain substrate disulfide pattern
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AspH is an endoplasmic reticulum (ER) membrane-anchored 2-oxoglutarate oxygenase
whose C-terminal oxygenase and tetratricopeptide repeat (TPR) domains present in the ER
lumen. AspH catalyses hydroxylation of asparaginyl- and aspartyl-residues in epidermal
growth factor-like domains (EGFDs). Here we report crystal structures of human AspH, with
and without substrate, that reveal substantial conformational changes of the oxygenase and
TPR domains during substrate binding. Fe(II)-binding by AspH is unusual, employing only two
Fe(II)-binding ligands (His679/His725). Most EGFD structures adopt an established fold
with a conserved Cys1–3, 2–4, 5–6 disulfide bonding pattern; an unexpected Cys3–4 disulfide
bonding pattern is observed in AspH-EGFD substrate complexes, the catalytic relevance of
which is supported by studies involving stable cyclic peptide substrate analogues and by
effects of Ca(II) ions on activity. The results have implications for EGFD disulfide pattern
processing in the ER and will enable medicinal chemistry efforts targeting human 2OG
oxygenases.
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The discovery that specific asparagine- and aspartate-residues in epidermal growth factor-like domains(EGFDs) undergo hydroxylation was a landmark in post-
translational modification (PTM) research, because it demon-
strated proteins other than collagen type domains are directly
modified by O2 (Fig. 1a)1,2. EGFD hydroxylation is catalysed by
the aspartate/asparagine-β-hydroxylase (AspH, BAH), a non-
haem ferrous iron and 2-oxoglutarate (2OG) oxygenase3–5, which
produces succinate and carbon dioxide as co-products. Human
ASPH (NCBI ID: 444 [https://www.ncbi.nlm.nih.gov/gene/?
term=444], AβH-J-J locus) has two promoters and undergoes
extensive alternative splicing6,7 resulting in >10 AspH isoforms
(Supplementary Fig. 1). An ASPH mutation resulting in the
R735W substitution correlates with Traboulsi syndrome (OMIM
601552/refSNP rs374385878), which manifests as facial dys-
morphism and lens dislocation8; another mutation (G434V)
affects human kidney function resulting in vesicoureteral reflux9.
AspH and its truncated, likely non-catalytic, isoform Humbug are
overexpressed in cancers10–14; AspH is strongly upregulated by
hypoxia15, consistent with its clinical use as a tumour
biomarker16,17. Loss of murine EGFD Asp/Asn β-hydroxylation
correlates with increased tumour incidence and developmental
defects similar to those caused by disrupted Notch signalling18.
AspH localises to the endoplasmic reticulum (ER) in normal cells,
but (at least part of AspH) localises to the surface of tumour
cells16,17 and its hydroxylase activity was reported to enhance cell
migration19,20.
EGFDs are ~40 residue domains often present in membrane
protein extracellular regions; their structures are primarily com-
prised of β-strands stabilised by 3 conserved internal disulfides,
which, as revealed by multiple crystal and NMR structures,
normally adopt a thermodynamically preferred canonical Cys1–3,
2–4, 5–6 disulfide pattern21–23. This disulfide pattern is a func-
tional requirement for some EGFDs24 and for Ca(II) ion bind-
ing25–27. AspH catalyses (3R)-hydroxylation of specific Asp/Asn
residues in EGFDs, some of which are involved in binding Ca(II)
in medicinally relevant proteins, e.g. as in coagulation factors,
Notch, Jagged, and Fibrillins28,29.
There are about 60 human 2OG oxygenases with a variety of
functional roles including in collagen biosynthesis, fatty acid
metabolism/carnitine biosynthesis, nucleic acid repair/modifica-
tion, O2 sensing, and transcriptional/translational regulation30.
Some 2OG oxygenases are therapeutic targets, including those
involved in carnitine biosynthesis and the hypoxia-inducible
factor hydroxylases31. Structurally informed sequence alignments
reveal most 2OG oxygenases possess a conserved His-Xxx-Asp/
Glu…His Fe(II)-binding motif located on β-strands II and VII of
the double-stranded β-helix (DSBH) core fold32. By contrast,
sequences of AspH indicate a His-Xxx-Gly…His Fe(II)-binding
motif33, though it has been unclear if an additional residue from
another part of AspH could be involved in Fe(II) binding. Despite
its importance in healthy biology and cancer, few biochemical
studies and no efficient substrates of isolated recombinant AspH
have been reported to date.
Here, we report crystallographic and biochemical results on the
structure and substrate selectivity of AspH. The results reveal a
key role for the TPR domain of AspH in substrate binding and,
unexpectedly, that the preferred EGFD-substrates of AspH have a
non-canonical (Cys3–4) disulfide pattern.
Results
AspH oxygenase domain structure. As precedented in work with
other multi-domain 2OG oxygenases34,35, we initially prepared
the isolated 2OG oxygenase domain of AspH for studies on
catalysis. Recombinant N-terminally hexa-His-tagged (His6)
AspH562–758 (AspH-Ox) was prepared in Escherichia coli (Sup-
plementary Fig. 2) and tested for catalytic activity using the N-
terminal EGFD of human coagulation factor X (hFX EGF139mer;
aa 86–124, Fig. 1b), a known cellular AspH substrate2,36, which
was prepared by solid-phase peptide synthesis followed by thiol
oxidation in air-saturated buffer to give disulfides. However, no
hydroxylation of hFX EGF139mer was detected by mass spectro-
metry (MS). Using a [1-14C]-2OG based assay, we observed
AspH-Ox catalysed turnover of 2OG to CO2 in the absence of
substrate, demonstrating oxygenase activity, albeit uncoupled
from substrate hydroxylation as precedented with some other
2OG oxygenases under certain conditions (Supplementary Fig. 3).
To investigate the predicted unusual Fe(II)-binding motif of
AspH, we initiated crystallographic studies. A structure of the
AspH oxygenase domain (AspH-Ox) was determined with Ni(II),
substituting for Fe(II), and with L-malate (from the crystallisation
buffer) bound in the predicted 2OG binding pocket (Supplemen-
tary Fig. 4). As expected, the AspH-Ox structure is comprised of 8
β-strands forming a double-stranded beta-helix (DSBH) fold,
with its active site located at the more open end of the β-
sandwich. In contrast to most 2OG oxygenases, the active site
metal is only coordinated by two histidine residues (His679,
His725), located on DSBH strands II and VII. Two water
molecules and a malate molecule complete octahedral coordina-
tion of the metal ion (Supplementary Fig. 4). Overall, the Asp-Ox
structure validates the expected DSBH fold with intact Fe(II) and
2OG-binding sites, consistent with the observed 2OG turnover.
To further investigate the lack of EGFD substrate hydroxylation
by the isolated AspH-Ox domain, we produced a longer AspH
construct containing the AspH-Ox and a predicted N-terminal
tetratricopeptide repeat (TPR) domain.
AspH oxygenase and TPR domain structure and activity. In
contrast to AspH-Ox, the longer AspH315–758 construct contain-
ing both 2OG oxygenase and TPR domains (AspH-TPR-Ox,
Supplementary Fig. 5) catalysed hydroxylation of hFX EGF139mer
at the anticipated Asp-residue (Asp103hFX, Fig. 1c–e). However,
incomplete substrate turnover (40%) was observed even with
prolonged incubation times and at higher enzyme-to-substrate
ratios using hFX EGF139mer synthesized by thiol oxidation in air-
saturated buffer. We next set out to obtain crystal structures of
AspH-TPR-Ox, in part aiming to rationalise the observed
incomplete substrate hydroxylation.
The longer AspH-TPR-Ox construct was crystallised in the
presence of Mn(II), substituting for the Fe(II) co-factor, and the
2OG analogue, N-oxalylglycine (NOG); L-malate was not
included in the crystallization buffer (Fig. 2 and Supplementary
Fig. 6). The oxygenase domain fold conformation in the AspH-
TPR-Ox structure is near identical to that of the AspH-Ox
structure (main chain RMSD 0.20–0.22 Å), with the largest
conformational differences occurring in an acidic loop (aa
614–620) which forms part of the active site (Supplementary
Figs. 7 and 8).
The solenoid-like TPR domain (aa 330–555) comprises 6
tandem repeating pairs of anti-parallel helices (12 helices in total,
α1–α12) and is connected to the AspH-Ox domain by a hinge-
loop region (aa 556–577) (Fig. 2a–c). Like that of AspH-Ox, the
AspH-TPR-Ox structure shows His679, His725, and two waters
coordinating the metal, but instead of malate, NOG is bound in
the 2OG binding pocket. The NOG C-5 carboxylate is positioned
to salt bridge with Arg735 and to hydrogen-bond with the Ser668
hydroxyl (which form a “RXS motif” as observed in some other
2OG oxygenases)31. The NOG oxalate is bound to the active site
via bidentate metal coordination and forms hydrogen bonds with
the side chains of His690 and Arg688 (Fig. 2d, e). This structure
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indicates that the R735W substitution, present in a Traboulsi
syndrome patient8, likely interferes with 2OG binding.
The major β-sheet of the DSBH core is flanked by seven helices
(α13–α19, Fig. 2a, b); the minor β-sheet is partially flanked by two
helices derived from the C-terminal repeats (repeat 6) of the TPR
domain. The 5 N-terminal TPR repeats form a right handed
superhelix, the concave face of which partially aligns to the
shorter linking loop end of repeats 2–4 that point towards the
oxygenase domain and help to form the active site (Fig. 2b, c).
The hinged oxygenase-TPR domain arrangement forms a large
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Fig. 1 EGF1 of human coagulation factor X undergoes AspH-catalysed hydroxylation at Asp103hFX. MS/MS-analysis was performed using a Bruker
Daltonics amaZonTM Ion Trap LC-MS/MS system equipped with a DionexTM UltiMate® 3000 HPLC machine. Endpoint turnover assays were performed
under standard (non-redox) conditions (for details see Methods section). For MS/MS-analysis, after quenching, cystine disulfides were reduced
(dithiothreitol) and cysteine thiols derivatized with iodoacetamide. a Reaction scheme for diastereospecific AspH-catalysed hydroxylation of Asp/Asn-
residues in EGFDs. b Schematic structure and calculated mass of the expected disulfide isomer of hFX EGF139mer (aa 86–124) featuring a canonical disulfide
connectivity pattern (Cys1–3, 2–4, 5–6; green); the hydroxylation site (Asp103hFX) is in red. c His6-AspH315–758 catalysed hydroxylation of hFX EGF139mer
proceeds with ~40% conversion under standard (non-redox) conditions; the light orange graph represents a control in which AspH was replaced by buffer.
d LC-MS/MS analysis of the relevant digestion fragment of hFX EGF139mer (aa 101–119), which is partially hydroxylated (~40%) after treatment with His6-
AspH315–758, confirms AspH-catalysed hydroxylation takes place at Asp103hFX as anticipated based on the AspH-substrate consensus sequence
(fragments bearing β-hydroxy-Asp are in red). e LC-MS/MS analysis of the relevant digestion fragment of hFX EGF139mer (aa 101–119) before exposure to
His6-AspH315–758
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and open cavity, in which we envisaged EGFD substrates may fit.
Comparison of the AspH TPR domain with other TPR domain
structures identified by a DALI search reveals variations in the
extent of curvature, likely due to the differences in intra-repeat
interactions and loop lengths. The AspH TPR repeats 1–5 align
particularly well with 5 repeats of the Candidatus magnetobacter-
ium bavaricum magnetosome-associated (MAMA) TPR-
containing protein (RMSD over 117 Cα atoms: 3.7 Å)37. The
AspH-TPR-Ox structure suggested that the TPR domain may be
directly involved in substrate binding. To investigate, we crystal-
lized AspH-TPR-Ox in the presence of the hFX EGF139mer
substrate.
AspH-TPR-Ox was successfully co-crystallized with a 39-
residue fragment of hFX EGF1 (AspH-TPR-Ox:hFX, Fig. 3 and
Supplementary Fig. 9). The AspH-TPR-Ox structure reveals
electron density at the active site corresponding to 18 of
the 39 hFX EGF1 substrate residues (aa 99–116:
-GKC3KDGLGEYTC4TC5LEGF-) and for a disulfide linkage
between Cys101hFX and Cys110hFX (Fig. 3e). Highly specific
interactions, including multiple protein–protein/peptide interac-
tions with both AspH-Ox and TPR domains are apparent
(Fig. 3b–d). The N-terminal region of hFX (aa 100–105) interacts
with the AspH-Ox domain and the C-terminal region of hFX (aa
106–116) interacts with the TPR domain. Comparison of AspH
structures with and without substrate implies that induced fit
involving substantial conformational changes during formation of
the AspH-TPR-Ox:hFX protein:protein complex occurs; the
distance between Leu433 on repeat 3 of the TPR domain to
Pro756 of the oxygenase domain near the C-terminus is reduced
from 20 to ~14 Å on substrate binding. This movement is
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Fig. 2 Crystal structure of AspH-TPR-Ox reveals Fe(II)-binding involving only two residues. Color code: grey: His6-AspH315–758; yellow: carbon-backbone of
N-oxalylglycine (NOG); violet: Mn; red: oxygen; blue: nitrogen. w: water. a Topology diagram of human AspH315–758. b Overview of the AspH-TPR-Ox
crystal structure. c Stereoview of the AspH-TPR-Ox crystal structure. d Close-up of the AspH-active site: Arg735 forms a salt bridge with the distal (C-5)
carboxylate oxygens of NOG (2.4 and 3.1 Å) while Ser668 interacts with one oxygen lone pair through a hydrogen bond (2.7 Å). His690 is positioned to
hydrogen bond to the C-1 carboxylate of NOG (2.8 Å). Mn(II) is bound to His679 (2.3 Å) and His725 (2.2 Å) of His6-AspH315–758 and coordinates two
water molecules (both 2.2 Å) as well as the C-1 (2.2 Å) and C-2 (2.5 Å) carbonyl oxygens of NOG. e Representative OMIT electron density map
(mFo–DFc) contoured to 3σ around NOG, Mn, water, and relevant AspH-active site residues are shown
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apparently enabled by the hinge region (aa 556–577) linking the
TPR and AspH-Ox domains (Fig. 4a, b).
The side chain of Asp103hFX, the substrate asparagine under-
going hydroxylation, is at the i+2 position of a Type I β-turn
adjacent to the active site metal and was modelled in two
conformations (A,B; see Supplementary Fig. 10 for details), both
of which are positioned to form salt bridges with the side chains
of Arg688 and Lys666 (Figs. 4c and 3e). The Asp103hFX
carboxylate side chain in conformation A is positioned to form
a hydrogen bond (3.2 Å) with the side chain of Gln627, whilst in
conformation B the carboxylate is positioned to interact with the
active site metal (2.6 Å) trans to His725. Asp103hFX conformation
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Fig. 3 Structure of AspH-TPR-Ox:hFX features a non-canonical EGFD disulfide connectivity. Color code: magenta: carbon-backbone of NC39mer peptide;
yellow: carbon-backbone of N-oxalylglycine (NOG); violet: Mn; red: oxygen; blue: nitrogen; pale yellow: sulfur. a Overview of the AspH-TPR-Ox:hFX
structure; His6-AspH315–758 in grey. b Surface representation (grey) of the AspH-TPR-Ox:hFX structure showing the substrate-binding groove, His6-
AspH315–758 in green. c Interactions of the TPR domain residues His493 and Arg526 as well as the hinge region residue Tyr565 with the NC39mer peptide.
d Additional interactions of the TPR domain with the NC39mer peptide: Asn395 forms a hydrogen bond with Phe116hFX (3.0 Å) and Phe432 forms a
hydrogen bond with Gly115hFX (3.2 Å). e OMIT electron density map (mFo–DFc) contoured to 3σ around the hFX derived NC39mer peptide supports the
presence of a non-canonical disulfide bridge between Cys101hFX and Cys110hFX as a substrate requirement for AspH (canonical EGFD disulfide isomer:
Cys1–3, 2–4, 5–6; non-canonical EGFD disulfide isomer: Cys1–2, 3–4, 5–6; see Fig. 5a). Note that electron density for two alternative conformation of the
Asp103hFX side chain is observed
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A is poised for C-3 hydroxylation such that its pro-3R-hydrogen
projects towards the metal (Cβ-metal distance ~4.5 Å) (Fig. 4d),
consistent with reported (3R)-stereoselectivity for AspH
catalysis1,36. The Asp103hFX conformation B displaces one of
the two metal coordinating waters that are observed in the AspH-
TPR-Ox structure without bound substrate.
Substrate binding to AspH also involves major changes within
an acidic loop which forms part of the active site (aa 614–620),
with the side chain carboxylates of Glu615, Asp616 and Glu617
all being shifted towards the substrate (Fig. 4b). The Glu617 side
chain is positioned to form a hydrogen bond (2.8 Å) with the
main chain amide nitrogen of Asp103hFX; the Asp616 side chain
is positioned to form a salt bridge with the Lys102hFX side chain;
and Glu615 folds into the inner apex of the acidic loop forming a
salt bridge with Arg620 and a hydrogen bond with the main chain
amide nitrogen of Leu619. In the AspH-Ox structure, the side
chain of Glu617 appears to mimic the Asp103hFX side chain
interactions with Lys666 and Arg688, possibly reflecting a
function for this residue in protecting the active site from
oxidation in the absence of substrate. In AspH-TPR-Ox:hFX
structure, the Arg686 side chain is positioned to form a hydrogen
bond with the main chain carbonyl oxygen of Lys102hFX and a
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Fig. 4 Significant conformational changes occur in AspH upon substrate binding. Color code: grey: His6-AspH315–758 (AspH-TPR-Ox:hFX); turquoise: His6-
AspH315–758 (AspH-TPR-Ox); magenta: carbon-backbone of NC39mer peptide; yellow: carbon-backbone of N-oxalylglycine (NOG); violet: Mn; red: oxygen;
blue: nitrogen; pale yellow: sulfur. w: water. a Superimposition of the AspH-TPR-Ox:hFX (grey) and AspH-TPR-Ox (turquoise) structures indicate
conformational changes in the TPR domain, the hinge region, and the oxygenase acidic loop on substrate binding. b Superimposition of the AspH-active
sites of the AspH-TPR-Ox:hFX (grey) and AspH-TPR-Ox (turquoise) structures: The interaction between Glu617apo and Arg620 (2.5 Å) in the AspH-TPR-
Ox structure is lost on substrate binding; both Asp616 and Glu617 interact with the substrate in the AspH-TPR-Ox:hFX structure. Gln627 (3.2 Å) and
Lys666 (2.7 Å) bind to the Asp103hFX carboxylate of the active conformer of the AspH-substrate. On substrate binding, the side chain of Glu615 rotates by
~90° to interact with the side chain of Arg620 (2.8 Å) and the main chain of Leu619 (2.8 Å), rather than Lys666 (2.7 Å) as in the substrate unbound state.
c The side chain of the Asp103hFX residue undergoing hydroxylation is observed in two conformations (A: magenta and B: pink; see Supplementary Fig. 10
for details). The Asp103hFX side chain carboxylate of conformation B (pink) is positioned (2.6 Å) to interact with the Mn. d Close-up of the AspH-active
site: The pro-R hydrogen at the Asp103hFX β-position of the likely productive NC39mer conformation A (magenta) is positioned to interact with the Mn
(distance Cβ-Mn: 4.2 Å), consistent with hydroxylation at this position
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-12711-7
6 NATURE COMMUNICATIONS |         (2019) 10:4910 | https://doi.org/10.1038/s41467-019-12711-7 | www.nature.com/naturecommunications
salt bridge with the Asp721 side chain. The position of the side
chains of Arg686, Arg688 and Asp721 in AspH-TPR-Ox:hFX
does not change in comparison with AspH-TPR-Ox.
Role of the TPR domain. Notably, the highly-conserved hFX
tyrosine, Tyr108hFX, that is part of the consensus EGFD sequence
for AspH hydroxylation38, binds in a mostly hydrophobic pocket
located between TPR repeats 5 and 6 located on the concave
surface of the TPR domain. The Tyr108hFX side chain hydroxyl is
positioned to form a hydrogen bond to the His493 side chain Nε2
(3.0 Å) and its main chain carbonyl to form a hydrogen bond
(2.8 Å) with the Arg526 side chain. The Tyr108hFX side chain is
apparently positioned to form skewed π-π-stacking interactions
with the side chains of Phe496 and Arg526. The main chain
nitrogen of Cys110hFX (2.9 Å) interacts with the Tyr565 side
chain (Fig. 3c).
At the hFX C-terminus, the phenyl ring of Phe116hFX is buried
in a hydrophobic pocket on the TPR domain formed by Ala389,
Leu398, and Phe432, which are located between TPR repeats 2
and 3. The phenyl ring of Phe116hFX is positioned to π-stack with
the Arg393 guanidine side chain and the peptide bonds linking
Arg393 with Ser394 and Asn395 (Fig. 3d). The Phe116hFX main
chain amide NH forms a hydrogen bond with the Asn395 side
chain Oδ1 (2.6 Å). Sequence alignment of known hydroxylated
EGFDs shows that the aromatic residues at the Phe116hFX
position are highly conserved (Supplementary Fig. 11).
Unexpectedly, in the AspH-TPR-Ox substrate complex we
observed a non-canonical disulfide bridge, i.e. between Cys101hFX
and Cys110hFX for the hFX substrate, in effect forming a ten-
residue ring (Fig. 3e). The substrate disulfide is positioned in a
hydrophobic pocket formed by Tyr565, Pro682, and Ile758. This
pocket is shared with Leu105hFX and expanded by Phe529 and
Leu564 of AspH.
The observed hFX disulfide corresponds to a non-canonical
Cys3–4 EGFD disulfide link, suggesting this pattern is required
for AspH catalysis rather than the established (Cys1–3, 2–4, 5–6)
disulfide pattern. The canonical EGFD disulfide pattern (Cys1–3,
2–4, 5–6) has been observed in all reported crystal and NMR
structures of EGFDs bearing the AspH-substrate consensus
sequence, including for hFX39,40. A non-canonical disulfide
pattern (Cys1–2, 3–4, 5–6) has been reported in crystalline and
solution state studies on the EGFD-5 of human thrombomodu-
lin41–43; this, however, does not have the AspH substrate
consensus sequence. MS44 and computational45 work also
suggests the possibility of a non-canonical disulfide connectivity
pattern for EGFDs bearing the consensus sequence for AspH-
catalysed hydroxylation. It was, therefore, important to investi-
gate AspH activity towards disulfide patterns with the non-
canonical 3–4 link (i.e. Cys1–2, 3–4, 5–6; 1–5, 3–4, 2–6; or 1–6,
2–5, 3–4).
AspH accepts an unexpected EGFD disulfide pattern. MS
analyses imply that the disulfide pattern arising from thiol oxi-
dation of the linearly synthesised hFX EGF139mer in air-saturated
buffer predominantly comprises a mixture of the canonical
(Cys1–3, 2–4, 5–6) and non-canonical (Cys1–2, 3–4, 5–6) dis-
ulfide patterns (Fig. 5a); other additional disulfide isomers may be
present in the mixture but were not detected. The canonical and
non-canonical disulfide isomers co-elute as a single peak in MS
coupled HPLC (Supplementary Figs. 12 and 13). Similar results
have been reported for the synthesis of EGFD5 of human
thrombomodulin46. The hFX EGF139mer mixture underwent
partial hydroxylation (~40%, Fig. 1c) by AspH-TPR-Ox under
normal assay conditions. However, it underwent complete
hydroxylation (>95%) when incubated with enzyme in a redox
buffer containing a mixture of reduced and oxidized glutathione
(GSH and GSSG). The conditions were employed to enable
reversible thiol-disulfide interchange of the canonical and non-
canonical hFX forms (Fig. 5b).
The complexities of the reversible nature of thiol-disulfide
interchange in solution render definitive identification of the
preferred disulfide pattern of the AspH EGFD substrate difficult.
We thus synthesised an irreversibly-linked cyclic analogue of the
Cys3–4 EGFD disulfide substrate; A 10mer cyclic peptide
(CP101–110) comprising the core residues (aa 101–110) of hFX
EGF139mer, wherein the Cys3–4 disulfide was replaced by a stable
thioether, was prepared using the method of Suga et al.47,48.
CP101–110 was efficiently Asp-β-hydroxylated by AspH-TPR-Ox
(~85%, Supplementary Figs. 14a and 15), whereas cyclic peptides
with variations in consensus sequence residues or a linear 10mer
peptide were not (Supplementary Fig. 14), further supporting the
crystallographically observed Cys3–4 disulfide as the preferred
substrate form for AspH catalysis. An extended 19mer CP
(CP101–119, Fig. 6a) was designed based on the enzyme-substrate
contacts observed in the AspH-TPR-Ox:hFX structure and found
to be a better substrate than CP101–110 (>95%, Fig. 6b). A
structure of AspH co-crystallised with the CP101–119 (AspH-TPR-
Ox:CP101–119) reveals this substrate bound to one of the two
AspH molecules in the asymmetric unit (chain A). Conforma-
tional differences between the bound (chain A) and unbound
(chain B) (Cα RMSD 3.82 Å) are consistent with afore-described
observations implying an AspH induced fit mechanism with hFX
(Fig. 6c and Supplementary Fig. 16).
Substrate variant analysis. Next, we assayed AspH for its ability
to hydroxylate truncated 26mer hFX EGF1 substrates (aa 86–111)
lacking the Cys5–6 disulfide-forming residues, synthesized using
orthogonal cysteine protection to yield selectively both the pure
canonical (C26mer, Fig. 7a) or non-canonical (NC26mer, Fig. 7d)
disulfide isomers. Only the NC26mer peptide was hydroxylated
under normal assay conditions (Fig. 7b, e), whereas both 26mer
peptides were hydroxylated using redox buffer conditions (Fig. 7c,
f). A structure of AspH in complex with NC26mer was obtained
(AspH-TPR-Ox:NC26mer, Supplementary Fig. 17). Comparison of
AspH-TPR-Ox:NC26mer and AspH-TPR-Ox:hFX structures
reveals little overall difference (Cα RMSD 0.13 Å). The presence
of a Cys3–4 disulfide bond indicates that the additional residues
present in the longer 39mer substrate, which were not observed in
electron density maps of AspH-TPR-Ox:NC26mer due to disorder,
are likely not essential for substrate recognition. The efficient
hydroxylation of the synthetic hFX EGF139mer with cysteines 1, 2,
5 and 6 (aa 90, 95, 112 and 121, respectively) all being replaced by
serines (NC-4Ser39mer) further supports the proposal that only the
substrate Cys3–4 disulfide is required for AspH-catalysed
hydroxylation (Fig. 8a–c). A structure of AspH in complex with
the NC-4Ser39mer substrate was obtained (AspH-TPR-Ox:NC-
Ser39mer, Supplementary Fig. 18). Comparison of the AspH-TPR-
Ox:NC-Ser39mer and AspH-TPR-Ox:hFX structures reveals little
overall difference (Cα RMSD 0.08 Å, Fig. 8d), including for the
Ser112NC-Ser39mer and Cys112hFX residues, suggesting that
Cys112hFX may not necessarily form a disulfide during productive
AspH-catalysis.
AspH with other EGFD protein substrates. To investigate the
generality of the hFX results, we tested recombinant Ca(II)-
binding EGFDs (cbEGFDs) (~10–15 kDa) from human Fibrillin-1
(hFib1); a two EGFD containing construct, cbEGF32-3349, a three
EGFD construct, cbEGF41-4350, and the single EGFD construct,
TB4cbEGF23 (with a cbEGFD preceded by a transforming growth
factor β-binding protein-like (TB) domain)51, and a three EGFD
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construct, cbEGF11-13, of Notch-1 (hNotch1)52. All these were
hydroxylated by AspH-TPR-Ox (30–85%) under redox buffer
conditions as determined by MS after proteolytic digestion, but
were much poorer substrates under non-redox conditions
(0–30%) (Supplementary Fig. 19).
Effect of calcium ions on EFGD stability and AspH activity. As
most AspH-substrate EGFDs bear a Ca(II)-binding site nearby
the AspH-hydroxylation site28, we next investigated if Ca(II) ions
inhibit EGFD hydroxylation, i.e. by stabilising the canonical
EGFD fold which is apparently not an AspH-substrate. No effect
on AspH-TPR-Ox activity was observed on addition of 3 mM Ca
(II) ions with any of the tested substrates in the absence of redox
buffer. By contrast, in the presence of redox buffer, hydroxylase
activity was not significantly affected for the recombinant multi-
domain proteins hFib1 (cbEGF32–33 and cbEGF41–43) and
hNotch 1 (cbEGF11–13). However, AspH hydroxylase activity
was substantially inhibited for the recombinant hFib1 fragment,
TB4cbEGF23 (aa 1527–1647, Fig. 9a), which binds Ca(II) tightly
(Kd= 16 ± 1 nM)51 and which is a poor AspH substrate under
non-redox hydroxylation conditions (<5% hydroxylation,
Fig. 9b), but an efficient one in redox buffer (~85% hydroxylation,
Fig. 9c). The addition of Ca(II) ions at 1 mM final concentration
in redox buffer reduced the extent of TB4cbEGF23 hydroxylation
from ~85 to ~25%; in the presence of 3 mM Ca(II) ions in redox
buffer TB4cbEGF23 hydroxylation was further reduced to ~10%
(Fig. 9d, e). No inhibitory effect was observed when 3 mM Mg(II)
was added instead of Ca(II) (Supplementary Fig. 20a). Ca(II) ions
do not directly inhibit AspH, as the irreversibly formed cyclic
thioether, CP2101–110, was fully hydroxylated in the presence of
10 mM Ca(II) (Supplementary Fig. 20b).
Since Ca(II) ions preferably bind to and stabilise the canonical
EGFD fold27, these results further support assignment of the non-
canonical 3–4 EGFD disulfide form as a preferred AspH
substrate. The effects of the neighbouring domains and the
different intrinsic Ca(II) affinities of EGFD proteins complicates
the understanding of the influence of Ca(II) ions on AspH-
catalysis. Nonetheless, the results clearly reveal the potential for
regulation of AspH activity by Ca(II) ions by stabilisation of
cbEGFDs in the canonical disulfide pattern fold, so making them
unavailable for disulfide shuffling to the non-canonical Cys3–4
pattern.
Discussion
There is an unmet need for further investigations into the
biological functions of human AspH and its role in genetic
diseases and cancer. Such work is challenging given the mem-
brane bound nature of AspH5, the presence of multiple dif-
ferent isoforms/splice variants (>10 in humans)6,7, its location
in the ER5, and the redox sensitive nature of its disulfide sub-
strates53. Our work defining the first substrates for isolated
AspH and the roles for the TPR domain in its catalysis provides
a structural basis for future work on the cellular and physio-
logical roles of AspH.
Whilst the oxygenase domain fold of AspH is typical for the
2OG oxygenase superfamily (Fig. 2), details of its active site and
the role of the TPR domain in EGFD-substrate binding are
remarkable. Key insights arising from our structures include: the
presence of an active site metal bound by only two protein
ligands, the role of the TPR domain in substrate binding, and the
fact that AspH only accepts EGFD-substrates with the non-
canonical Cys3–4, instead of the canonical Cys1–3, 2–4, 5–6,
disulfide pattern. The latter finding was unexpected given the
prevalence of the canonical EGFD disulfide pattern (at least
outside of the ER) reported in the literature54. The lack of in vitro
hydroxylation assays for AspH has hindered progress on its
characterisation; our results will enable further detailed kinetic,
mechanistic, and inhibition studies on AspH.
Comparison of the AspH structures with and without sub-
strates implies substantial induced fit during substrate binding
(Fig. 4a, b); experience with NMR studies on single oxygenase
domain 2OG oxygenases55–57 implies that in the case of AspH,
even more substantial changes in conformation may occur in
solution, likely involving both oxygenase and TPR domains, as
well as AspH-substrates. Whatever the precise extent of con-
formational changes during catalysis, the results reveal a central
role for the TPR domain in enabling AspH catalysis—without it,
2OG turnover occurs, but EGFDs are not hydroxylated (Fig. 4
and Supplementary Fig. 3).
TPR domains are involved in protein-protein interactions and
substrate recognition in other proteins/enzymes58 including
human 2OG oxygenases, i.e. the procollagen C-4 (CP4Hs) and C-
3 (Leprecans) prolyl- and C-5 (PLODs) lysyl-hydroxylases, which
contain (or are predicted to contain) TPR domains N-terminal to
the oxygenase domain59. As yet, there are no structures reported
for the oxygenase domains of eukaryotic members of these TPR
containing enzymes, which like AspH are ER localised, though
the TPR domain of CPH in complex with a collagen-like peptide
has been structurally characterised60. Our work reveals how the
AspH oxygenase and TPR domains recognise and bind a non-
canonical 3–4 disulfide EGFD and, through conformational
changes to the enzyme, guide and position the Asp/Asn residue to
be hydroxylated to the active site in a catalytically productive
hFX EGF139mer (aa 86–124, canonical Cys 1–3, 2–4, 5–6):
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Fig. 5 AspH fully hydroxylates a mixture of canonical and non-canonical EGFD disulfides under redox conditions. End-point turnover reactions were
performed as in the Methods Section. a Schematic structures of the two major hFX EGF139mer disulfide isomers identified in a single batch of hFX EGF139mer
obtained by thiol oxidation in air-saturated buffer (see Supplementary Information); disulfides are in green (canonical isomer, Cys1–3, 2–4, 5–6, top; non-
canonical isomer, Cys1–2, 3–4, 5–6, bottom), the hydroxylation sites (Asp103hFX) are in red. b >95% Hydroxylation of hFX EGF139mer was observed under
redox conditions as opposed to partial hydroxylation under standard (non-redox) conditions (Fig. 1c), indicating that a ‘non-canonical’ EGFD-disulfide
pattern (Cys 1–2, 3–4, 5–6) is the actual AspH-substrate; the light orange graph represents a control in which AspH was replaced by buffer
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Methods Section. a Schematic structure and calculated mass of the cyclic peptide CP101–119 mimicking the central macrocyclic disulfide of the non-canonical
isomer of hFX EGF139mer (Cys3–4); the hydroxylation site (Asp103hfX) is in red. b >95% Hydroxylation of the CP101–119 peptide was observed under
standard (non-redox) conditions; the light orange graph represents a control in which AspH was replaced by buffer. c Two His6-AspH315–758-molecules are
present in the asymmetric unit of the AspH-TPR-Ox:CP101–119 crystal structure, only one binds the CP101–119 peptide (details in the Supplementary
Information): The superimposition of the two independent AspH-molecules of this crystal structure (colour code: unbound AspH: raspberry; AspH bound
to CP101–119: grey; CP101–119: green) highlights an induced fit mechanism of AspH upon substrate binding: Major conformational changes occur in the TPR
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(see Supplementary Figure 16 for further details)
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manner. It would seem probable that some of the TPR domains
in other ER-localised 2OG oxygenases have analogous roles.
The role of the TPR domain in AspH catalysis is precedented
in the roles of some non-catalytic domains in substrate targeting
by the 2OG dependent JmjC Nε-methyl lysine histone demethy-
lases (KDMs), though this is only understood in detail from a
structural perspective for two KDM7 subfamily members
(KDM7A/B)61. Binding of a highly-conserved EGFD tyrosine
(e.g. Tyr108hFX) to a hydrophobic pocket on the TPR domain
surface is reminiscent of H3K4me3 binding to the plant
homeobox domain (PHD) of KDM7A61. Analogous recognition
domains to that of KDM7A/B occur in other JmjC KDMs,
involving different domain types (e.g. Tudor domains), though to
our knowledge TPR domains are not present in the chromatin
modifying 2OG oxygenases; they thus appear to be characteristic
of the ER localised 2OG oxygenases.
The combined results reveal that AspH accepts EGFD sub-
strates with a non-canonical Cys3–4 disulfide pattern, rather than
the canonical Cys1–3, 2–4, 5–6 pattern. Evidence for this comes
from structural data, MS turnover assays under different redox
conditions, inhibition by Ca(II) ions (which presumably bind and
stabilise the canonical but not the non-canonical disulfide pat-
tern), and the use of a stable disulfide cyclic peptide analogue.
These observations are interesting because they raise the possi-
bility of EGFDs manifesting dynamic disulfide patterns in the
redox active environment of the ER, rather than being limited to
the canonical form normally observed by in vitro biophysics and
which current evidence implies would likely be dominating in the
oxidising extracellular environment. Indeed, the combined crys-
tallographic evidence suggests the canonical form is the most
thermodynamically stable21–23. AspH could act as a chaperone
regulating EGFD folding or recognising misfolded EGFDs, pos-
sibly as part of the redox sensitive unfolded protein response
(UPR) pathway62. This is consistent with the identification of
various degrees of β-hydroxylation in purified native proteins
containing EGFDs, most notably human coagulation proteins
hFIX (30%) and hFX (100%)63, which implies they have been
through a folding cycle prior to secretion into the bloodstream.
Interestingly, purified hFVII does not show any β-hydroxylation,
despite having the AspH-substrate consensus sequence, which
suggests a possible role of AspH in recognising misfolded rather
than functionally active folded EGFDs. One role of AspH could
be to regulate EGFD folding with hydroxylation being an oxygen
sensitive element of this process rather than an end in itself; this
proposal is consistent with the lack of observed effect of Asn/Asp
hydroxylation on the canonical EGFD fold conformation and on
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Fig. 7 The EGFD disulfide connectivity determines the degree of AspH-catalysed hydroxylation under non-redox conditions. End-point turnover reactions
were performed as in the Methods Section. Light orange graphs represent controls in which AspH was replaced by buffer. a Schematic structure and
calculated mass of the C26mer peptide, bearing a canonical disulfide arrangement (Cys1–3, 2–4); disulfides are shown in green, the hydroxylation site
(Asp103hFX) is indicated in red. b No hydroxylation of the C26mer peptide was observed under standard (non-redox) conditions; ~7% impurity (might
correspond to an oxidized byproduct) was observed in this sample, including the control samples. c >95% Hydroxylation of the C26mer peptide was
observed under redox conditions. d Schematic structure and calculated mass of the NC26mer peptide, bearing a non-canonical disulfide arrangement
(Cys1–2, 3–4); disulfides are in green, the hydroxylation site (Asp103hFX) is in red. e >95% Hydroxylation of the NC26mer peptide was observed under
standard (non-redox) conditions. f ~83% Hydroxylation of the NC26mer peptide was observed under redox conditions
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Ca(II) ion binding63. Extracellular AspH could play a role in
recognising and labelling mis-folded EGFDs on the cell surface,
possibly in a manner relating to over-production of AspH in
cancer cells10,11,13,16,17, since the latter can have dysregulated
EGFD proteins involved in signalling (e.g. Notch)64,65. The
structures reported here may also of be interest with respect to
defining factors involved in AspH localisation, in particular to the
surfaces of some tumour cells16,17. They raise the possibility of
AspH localisation being regulated by EGFD binding in a manner
dependent on the EGFD disulfide pattern and redox environ-
ment. The results also suggest that AspH activity may be regu-
lated by Ca(II) ions; in this regard it is interesting that there are
predicted Ca(II) binding EF-hand motifs in human AspH itself.
The results clearly reveal that, at least under the analysed
conditions, AspH has an unusual Fe(II) coordination chemistry
for a 2OG-dependent hydroxylase (Fig. 2d, e). It should be noted
that all the AspH crystal structures presented here are in complex
with Ni(II) or Mn(II) and a 2OG mimetic, i.e. NOG or L-malate.
We considered the possibility that in the presence of Fe(II) and
2OG a third protein-derived ligand interacts with the metal.
However, this scenario seems unlikely given that the metal
coordination geometries and substrate positions observed in
many other 2OG-dependent oxygenase crystal structures in
complex with Fe(II) and 2OG compared to Ni(II)/Mn(II) and
NOG are very similar, with no evidence for additional enzyme
derived ligands being observed31.
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The reason why AspH employs two- rather than three-protein
derived metal ligands is unclear, but sequence comparisons sug-
gest this is a highly-conserved feature (Supplementary Fig. 6). It
also appears to be linked to other characteristic active site features
involving 2OG and substrate binding, which may compensate for
the lack of a third protein ligand. It is of interest that in the
structure of AspH-TPR-Ox complexed with a 39-residue frag-
ment of hFX EGF1 (AspH-TPR-Ox:hFX, Fig. 4) the Asp residue
positioned for AspH-catalysed hydroxylation is observed in two
conformations. One conformer is apparently positioned for ste-
reoselective hydroxylation in a manner precedented for other
2OG oxygenases (Supplementary Fig. 21). By contrast, the Asp
side chain carboxylate of the other conformer is positioned to
coordinate with the active site metal (Fig. 4). Whilst the latter
conformation may be involved in catalysis, it may be that within
the endoplasmic reticulum, AspH substrates are involved in
maintaining Fe(II) at its active site.
The unusual coordination chemistry of AspH may relate to an
as yet undetermined physiological or disease role as it is the case
for the 2OG dependent hypoxia-inducible factor (HIF) prolyl
hydroxylases (PHDs), where it is proposed that the unusual
kinetic properties of PHDs, i.e. their slow reaction with O2, both
reflect their active site chemistry and roles as hypoxia sensors31.
Given the unusual coordination chemistry of AspH, detailed
kinetic and solution biophysical studies to investigate dioxygen
binding and water ligand displacement are of considerable
interest and are the subject of ongoing work.
We compared the AspH structures with the human HIF Asn-
hydroxylase, factor inhibiting HIF (FIH, PDB: 1H2K)66, and a
prokaryotic asparagine hydroxylase, AsnO (PDB: 2OG7)67
(Supplementary Fig. 21). Analysis of enzyme-substrate complex
structures reveals similar substrate side chain orientations at the
active sites of AsnO and FIH, consistent with knowledge that they
produce the same (3S)-stereochemistry products67,68, which
contrasts with the (3R)-product of AspH1,36. AsnO has an active
site arginine (Arg305AsnO), which interacts with the Cα carbox-
ylate of the asparagine substrate, similarly to the interaction of
AspH Arg688 with the side chain of Asp103hFX (Supplementary
Fig. 20). However, Arg305AsnO is located on β-strand VIII and
AspH Arg688 is located on β-strand III of their respective
DSBHs, possibly reflecting convergent evolution within the 2OG
oxygenase superfamily. Interestingly, FIH also interacts with the
side chain of its Asn (and Asp) substrates using an arginine,
Arg238FIH, but one which is located on an insert linking DSBH β-
strands βIV-V (Supplementary Fig. 21). Biochemical and struc-
tural studies on FIH metal binding carboxylate variants D201A
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digested using trypsin, and analysed using MALDI-ToF-MS. Light orange graphs represent controls in which AspH was replaced by buffer. a Sequence of
the fragment of human fibrillin-1, TB4cbEGF23 (hFIB1_TB4cbEGF23, aa 1527–1647; Uniprot Database entry: FBN1_HUMAN), bearing the hydroxylation site
(Asn1624hFIB1, red). b <5% Hydroxylation was observed under standard (non-redox) conditions. c ~85% Hydroxylation was observed under redox
conditions. d ~25% Hydroxylation was observed under redox conditions in the presence of 1 mM Ca(II). e ~10% Hydroxylation was observed under redox
conditions in the presence of 3 mM Ca(II)
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and D201G reveal coordination by only two His residues and that
the D201G variant is catalytically viable69. Comparison of these
structures with AspH shows the main chain Cα of the carboxylate
ligand positions are very similar, but that the hFX substrate
residue side chain likely causes changes in metal geometry. It is
probable that second sphere residues, including the substrate side
chain, contribute to catalysis in the two-His metal binding 2OG
oxygenases. 2OG dependent halogenases (SyrB2/CytC3/WelO5/
AmbO5) also have two His metal binding ligands (His-Xxx-Ala…
His motif), an arrangement enabling halide coordination to the
active site metal70. We have not observed halogenase activity with
AspH in the presence of chloride ions, implying other factors in
addition to the number of metal ligands control substrate
hydroxylation versus halogenation.
The ability to carry out assays with isolated AspH and
knowledge of its active site and substrate binding mode provide a
platform from which to develop small molecule AspH inhibitors.
These will be useful in dissecting its biological functions and will
help to enable new cancer treatments and the development of
selective inhibitors for other human 2OG oxygenases, some of
which are current medicinal chemistry targets71.
Methods
Recombinant protein production and purification. A pET-28a(+) vector
encoding for N-terminally His6-tagged AspH315–758 was transformed into E. coli
BL21 (DE3) cells. Cells were grown in 2TY media supplemented with kanamycin
(0.05 mM; 30 mg/ml) at 37 °C with shaking (180 rpm). AspH production was
induced by adding isopropyl ß-D-thiogalactopyranoside to a final concentration of
0.1 mM when the OD600 reached 1.2 at 18 °C. Cells were shaken for 16 h at 18 °C,
then harvested by centrifugation (10,967 × g, 8 min, 4 °C); the resultant cell pellets
were stored at –80 °C. The frozen cell pellets were resuspended in ice-cold (30 g/
100 mL) 50 mM HEPES buffer (pH 7.5, 500 mM NaCl, 5 mM imidazole) con-
taining EDTA-free protease inhibitor cocktail tablets (1 tablet/50 mL, Roche
Diagnostics) and DNAse I (bovine pancreas, grade II, Roche Diagnostics). Cells
were lysed by sonication on ice (8 × 30 s bursts; Sonics Vibra-Cell VCX500,
amplitude: 60%) and the lysate was centrifuged (48,384 × g, 30 min, 4 °C). The
supernatant containing AspH was purified at 4 °C using Ni(II)-affinity chroma-
tography (HisTrap HP column, GE Healthcare) on an ÄKTA Pure machine (GE
Healthcare) with a step elution gradient (to 50 mM HEPES, pH 7.5, 500 mM NaCl,
40 mM imidazole) and elution buffers (50 mM HEPES, pH 7.5, 500 mM NaCl, 500
mM imidazole; AspH typically eluted at around 150-200 mM imidazole). Eluted
fractions containing AspH were pooled, concentrated using Amicon Ultra cen-
trifugal filters (3082 × g, 4 °C), and further purified by size-exclusion chromato-
graphy using a HiLoad 26/60 Superdex 75 pg 300 mL column with a flow rate of
1 mL/min and 50 mM HEPES (pH 7.5, 500 mM NaCl) as elution buffer. The
protein was subsequently concentrated and buffer exchanged into 50 mM HEPES,
pH 7.5 for storage at −80 °C until further use. Purity of the proteins was assessed
by SDS-PAGE and MS (Supplementary Fig. 5).
AspH-substrates. A 39mer peptide based on the amino acid sequence of the first
EGFD of hFX (hFX EGF139mer, aa 86–124) was synthesized by solid phase peptide
synthesis (SPPS) and purified by Peptide Synthetics (Peptide Protein Research Ltd,
UK). Regioselective disulfide formation to yield exclusively (within our analytical
limits) the canonical disulfide pattern (Cys1–3, 2–4, 5–6) was achieved using a
sequence of orthogonal cysteine protection and selective cysteine oxidation72:
However, no hydroxylation of this peptide was observed when exposed to His6-
AspH315–758 and cofactors. Therefore, the 39mer peptide was resynthesized with
the disulfide bridges being formed by thiol-oxidation in air-saturated buffer. This
method has previously been applied to synthesize bovine FX4 and FIX24 peptides
that were successfully hydroxylated by bovine AspH. Using this protocol, a mixture
of the canonical (Cys1–3, 2–4, 5–6; C39mer) and non-canonical (Cys1–2, 3–4, 5–6;
NC39mer) disulfide-isomers was obtained (Supplementary Fig. 12 and 13), which
was used in all subsequent hydroxylation assays. Derivatives of hFX EGF139mer
containing either canonical (C26mer) or non-canonical (NC26mer; NC-4Ser39mer)
disulfides were synthesized as single disulfide isomers by GL Biochem (Shanghai)
Ltd using orthogonal cysteine protection. The Ca(II)-binding EGFD-containing
multi-domain AspH-substrates (hFIB1_cbEGFD32–3349, hFIB1_cbEGFD41–4350,
hFIB1_TB4cbEGF2351, hNotch1_cbEGFD11–1352) were produced recombinantly
in E. coli and purified as reported in the cited literature.
Design and synthesis of cyclic peptides. Based on the AspH-TPR-Ox:hFX
crystal structure, stable cyclic peptides comprising the core ring residues (aa
101–110) of the hFX EGF139mer-substrate with a thioether replacing the Cys3–4
disulfide were synthesized. The D-stereochemistry of the N-terminal amino acid
(aa 101) aligns the peptide side chain with the main chain of the original substrate.
Commercial Fmoc-protected amino acids (AGTC Bioproducts; Alfa Aesar;
CSBio; Iris Biotech; Novabiochem; Sigma-Aldrich; TCI) were used as received.
SPPS was performed using a CSBio CS336X automated peptide synthesizer
following standard Fmoc-strategy: linear peptides were synthesized from the C- to
N-termini on a 0.1 mmol scale using a Rink amide linker using N,N-
diisopropylcarbodiimide/1-hydroxybenzotriazole for coupling.
To obtain cyclic peptides, the N-terminal Fmoc-protecting group was cleaved
on the resin, and the resin suspended in DMF (4 mL) containing N-
chloroacetylsuccinimide73 (150 mg). The mixture was gently shaken for 3 h,
filtered, and the dried resin treated with a solution of trifluoroacetic acid,
triisopropylsilane, and water (4 mL; 95/2.5/2.5). After 3 h, the mixture was filtered
and the solution diluted with 45 mL cold diethyl ether. The suspension was
centrifuged (4000 rpm, 10 min, 4 °C), decanted, and then taken up in 1.5 mL
aqueous triethylammonium acetate buffer (1 M, pH 8.5, pH readjusted with
trimethylamine) and heated for 10 min at 100 °C in a microwave reactor (Biotage
Initiator). Directly afterwards, the crude cyclic peptides were purified by semi-
preparative HPLC (DionexTM UltiMate® 3000, Thermo Scientific) using a reverse
phase column (Grace Vydac® 218TP101522) and a gradient of acetonitrile in
milliQ water (each containing 0.1%v/v trifluoroacetic acid) specified in
Supplementary Fig. 14.
AspH activity assays. All reagents were obtained from commercial sources (Alfa
Aesar; Sigma-Aldrich; TCI). For all turn-over experiments, His6-tagged AspH-
constructs were used, as no effect upon cleavage of the His6-tag was observed in
initial activity assays. Hydroxylation assays were initialised by mixing a solution
containing AspH (10 μM), L-ascorbic acid (400 μM), and (NH4)2Fe(SO4)2·7H2O
(50 μM) in the appropriate buffer with a solution containing substrate (100 μM),
disodium 2-oxoglutarate (300 μM), and, if desired, additional reagents (CaCl2,
EGTA) in the appropriate buffer. The buffers used comprised: Standard, non-
redox, Buffer (50 mM HEPES pH 7.5, 150 mM NaCl); Redox Buffer (50 mM Tris,
pH 8.5, 3.0 mM reduced L-glutathione, 0.3 mM oxidized L-glutathione, 150 mM
NaCl); Refolding Buffer (50 mM Tris, pH 8.5, 3.0 mM L-cysteine, 0.3 mM L-
cystine, 10 mM CaCl2). Reactions were performed at 37 °C for 60 min unless
otherwise noted, and then quenched by the addition of an equal volume of 1%v/v
aqueous formic acid. All assays were performed in triplicate alongside an additional
no-enzyme control (His6-AspH substituted by buffer).
The hydroxylase activity of AspH was assayed by MALDI-ToF MS in the
positive ion reflectron mode (Bruker Daltonics Ultraflex I machine with 32–60%
laser energy; Waters Micromass MALDI micro MX with flight tube voltage: 12 kV,
reflectron voltage: 5.2 kV, laser fire rate: 10 Hz, pulse voltage: 1950 V, detector
voltage: 2750 V): the relative quantities of substrate and hydroxylated product were
analysed with respect to no-enzyme controls. A 1:4 volume ratio of sample to
MALDI-matrix was used for sample preparation (20 mg/mL 2,5-dihydroxybenzoic
acid, 10 mg/mL α-cyano-4-hydroxycinnamic acid or 10 mg/mL sinapinic acid in
aqueous 50% CH3CN containing 0.1%v/v trifluoroacetic acid). For the disulfide
containing substrates a matrix composed of a 10:1 mixture of 10 mg/mL α-cyano-
4-hydroxycinnamic acid:10 mg/mL 2-(4′-hydroxybenzeneazo)benzoic acid in
aqueous 50%v/v CH3CN containing 0.1%v/v trifluoroacetic acid was used. Mass
spectra were analysed using MassLynx software (Version 4.1). Apart from the
AspH-substrate peaks, peaks corresponding to the desired AspH-substrate mass
reduced by 18 Da are frequently observed in the MALDI-MS spectra; these peaks
result from the ionization induced liberation of H2O upon intramolecular
cyclization of aspartates to form aspartyl succinimides (−18 Da)74 and are taken
into account when integrating the peaks to determine conversions.
Crystallography. Crystals of N-terminally His6-tagged AspH562–758 were grown by
the vapour diffusion method at 20 °C in 150 nL sitting drops. The drops were
prepared by mixing 100 nL of protein solution (9.5 mg/mL containing 1 mM N-
oxalylglycine (NOG) and 10 mM NiSO4) and 50 nL of precipitant (50 mM dis-
odium malate, 30%v/v PEG-3350, 30% dextran sulfate sodium salt) with a protein
to well ratio of 1:2. Crystals were cryo-cooled in liquid N2 with 25% glycerol as
cryoprotectant and data were collected at 100 K using synchroton radiation at the
Diamond Light Source (DLS).
For the remaining structures, high-throughput crystallization screens were set
up using a Phoenix RE liquid dispensing robot (Art Robbins Instruments) on 96-
well, 3-subwell low profile Intelliplates (Art Robbins Instruments) using Hampton
Research Molecular Dimensions crystallization screens (JCSG plus, PACT, INDEX,
PEG/Ion, Structure, Salt, MIDAS) or optimization screens. N-Terminally His6-
tagged AspH315–758 (18 mg/mL in 50 mM HEPES buffer, pH 7.5) was mixed with 1
mM MnCl2 (pH 7.5), 2 mM N-oxalylglycine (pH 7.5), and, when appropriate, an
AspH-substrate (see Supplementary Table 1 for details). Crystals were grown by
the vapour diffusion method at 4 °C in 200 or 300 nL sitting drops using 2:1, 1:1 or
1:2 sample:well solution ratios. Crystals were cryoprotected using mother liquor
supplemented with 25%v/v glycerol before cryo-cooling in liquid N2. Data were
collected at 100 K at DLS. Data were indexed, integrated, and scaled using HKL-
300075, XDS76, SCALA77, Xia278 or CrystalClear (Rigaku). Detailed crystallization
conditions for all crystal structures and a summary of data collection parameters
are given in Supplementary Table 1.
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Structure solution and refinements. The structure of AspH-Ox was determined
by single isomorphous replacement with anomalous scattering (SIRAS). Briefly,
AspH crystals were derivatised by incubating in a reservoir solution supplemented
with 10 mM K2PtCl4 for 5 h. Crystals were transferred to and backsoaked for
several seconds in a reservoir solution supplemented with 25% ethylene glycol
instead of Pt(II) and crystals were immediately cryo-cooled in liquid N2.
The AspH-Ox (native and Pt-derivatised) datasets were integrated (XDS76) and
subsequently scaled (SCALA). SHELXD79 was used to locate three platinum
positions in the Pt-dataset. Heavy atom positions were refined and initial phases
calculated with SHARP80 using the SIRAS method. The final electron density map
after phase extension and solvent flattening with SOLOMON81 was of excellent
quality and automated model building with ARP/wARP82 resulted in a 95%
complete model. Refinement with PHENIX83 and several rounds of manual
rebuilding in COOT84 resulted in a model with a final Rfactor/Rfree of 15.3/18.6%,
respectively.
The AspH-TPR-Ox structure was determined by molecular replacement (MR)
using the AutoMR (PHASER85) subroutine in PHENIX. The coordinates of the
AspH oxygenase domain (His6-tagged AspH562–758 as a search model, PDB: 5APA)
were first used to successfully identify a rotation and translation solution for the
oxygenase domain. Initial attempts to find a rotation and translation solution for
the TPR using the C-terminal TPR domain of peroxisomal targeting signal 1
receptor (PEX5)86 were complicated by the repeating nature of the TPR fold. In
order to overcome problems associated with the repeating fold the search model
was trimmed to include three sequential repeats (PEX5 Gln300-Tyr395, PDB:
1FCH). The 3 C-terminal TPR repeats of AspH were identified in a search after the
oxygenase domain was fixed. This allowed manual fitting of 3 further TPR repeats
to the N-terminus of AspH. Rigid body refinement of the three separate fragments
followed by simulated annealing refinement (both cartesian and torsion) led to a
model with Rfree 42.15. Iterative rounds of model building and fitting in COOT84
and refinement in PHENIX83 were performed until the decreasing R and Rfree no
longer converged and a final model was obtained. Due to domain movements
between different crystal forms and complexes, all other structures were
determined by MR using PHASER with the oxygenase and TPR domains searched
for independently. The oxygenase domain was always searched first followed by the
TPR domain. For data from crystals grown in the presence of substrate, up to 18
residues of bound substrate were modelled. Refinement statistics are given in
Supplementary Table 2. Representative electron density (with contour level and
map types defined in legends) is shown in Figs. 2 and 3 and in Supplementary
Figs. 4, 7, 16–18.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Crystal structure data for N-terminal His6-tagged AspH562–758 and N-terminal His6-
tagged AspH315–758 (apo and in complex with different AspH-substrates) are deposited in
the protein databank with PDB accession codes: 5APA (AspH-Ox), 5JZA (AspH-TPR-
Ox), 5JZ6 (AspH-TPR-Ox:malate), 5JZ8 (AspH-TPR-Ox:hFX), 5JQY (AspH-TPR-Ox:
NC-Ser39mer), 5JZU (AspH-TPR-Ox:NC26mer), 6RK9 (AspH-TPR-Ox:CP101–119). Other
data are available from the corresponding author upon reasonable request.
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